搜索结果
靶点ID:TCMBANKGE001052
靶点别名:AGTAVPRL; AII; AVP; C1orf7; CIAS1; CLR1.1; DFNA34; FCAS; FCAS1; FCU; KEFH; MWS; NALP3; PYPAF1
靶点描述:NLR family pyrin domain containing 3
染色体:1
染色体位置:1q44
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:16400
OMIM_Link:606416
Ensembl_Link:ENSG00000162711
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000029 | colchicine | LS-187917 | C22H25NO6 | 399.44 | CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC |
| TCMBANKIN000096 | oridonin | Rub A | C20H28O6 | 364.4 g/mol | CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C |
| TCMBANKIN000167 | deoxyandrographiside | CC1=CC(=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)O)O | |||
| TCMBANKIN036802 | ellagic acid | 2,3,7,8-Tetrahydroxy(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione; 4,4',5,5',6,6'-hexahydroxydiphenic acid 2,6,2',6'-dilactone; CE0034; 5-19-07-00108 (Beilstein Handbook Reference); AS-12615; ellagic acid ; LTK-20; 133039-73-3; ellagicacid; NE58729; 2,3,7,8-Tetrahydroxy(1)benzopyrano(5,4,3-cde)-(1)benzopyran-5,10-dione; AIDS002688; Spectrum3_001535; SBB006501; 4,4′,5,5′,6,6′-Hexahydroxydiphenic acid 2,6,2′,6′-dilactone; Llagic acid; BRN 0047549; 2,6,2',6'-dilactone hydrate; 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; KBio2_004242; Polyphenolic; NCGC00094975-01; Eleagic acid; MFCD00149494; MolPort-000-705-556; 2,3,7,8-tetrahydroxy[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione; [1]Benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-; EINECS 207-508-3; NCGC00017245-01; NCI60_003869; Ellagsaeure; Ellagic Acid, Dihydrate; Diphenic acid, 4,4',5,5',6,6'-hexahydroxy-, di-.delta.-lactone; KBio3_002450; MLS-0066664.0001; KBio2_006810; SCHEMBL2639621; Ellagic acid hydrate, 97%, may cont. up to 12% water; Ellagic acid dihydrate; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0,(1).0(1)(1),(1)]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione dihydrate; Spectrum2_000905; Gallogen (astringent); TNP00132; KBioSS_001674; MLS000069632; SMP1_000111; (1)Benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-; BSPBio_002950; Oprea1_032884; C.I. 75270; NSC656272; SPBio_000750; NSC 656272; BCBcMAP01_000154; Elagostasine; I14-61927; NSC 407286; BB_NC-0491; C10788; C.I. 55005; 2,3,7,8-Tetrahydroxy[1]benzopyrano-[5,4,3-cde][1]benzopyran-5,10-dione; Spectrum_001194; Gallogen, astringent; SMR000058244; CHEBI:4775; SPECTRUM1502245; KBio2_001674; KBioGR_001080; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0^{4,16}.0^{11,15}]hexadeca-1(15),4(16),5,7,11,13-hexaene-3,10-dione dihydrate; Acido elagico [INN-Spanish]; BG00667714; 476-66-4; Benzoaric acid; AK186482; SDCCGMLS-0066664.P001; Z1551861526; CCRIS 774; Gallogen (VAN); NSC407286; Ellagic acid [DCF:INN]; [1,1'-Biphenyl]-2,2'-dicarboxylic acid, 4,4',5,5',6,6'-hexahydroxy-, di-.delta.-lactone; CCG-208140; NCGC00094975-02; 4,4′,5,5′,6,6′-Hexahydroxydiphenic Acid 2,6,2′,6′-Dilactone; Spectrum4_000750; Alizarine Yellow; 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0?,??.0??,??]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione dihydrate; Diphenic acid, 4,4',5,5',6,6'-hexahydroxy-, di-delta-lactone; AIDS-002688; AKOS025310087; Acidum ellagicum [INN-Latin]; Lagistase; ZINC00058174; C14H6O8.2H2O; Spectrum5_000959; E2250_SIGMA; Acide ellagique [INN-French]; NCGC00094975-03; 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione dihydrate; Ellagic acid | C14H6O8 | 302.193 | c1(O[H])c([H])c2c(c(c(C(=O)O3)c([H])c(O[H])c4O[H])c4OC2=O)c3c1O[H] |
| TCMBANKIN036827 | xanthohumol | CHEBI:134289; xanthohumol(1-); 2',4,4'-trihydroxy-6'-methoxy-3-prenylchalcone; 3-hydroxy-6-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-5-methoxy-2-(3-methylbut-2-en-1-yl)phenolate | C21H22O5 | 354.4 | CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C |
| TCMBANKIN036877 | gedunin | C28H34O7 | 482.6 g/mol | CC(=O)OC1CC2C(C(=O)C=CC2(C3C1(C45C(O4)C(=O)OC(C5(CC3)C)C6=COC=C6)C)C)(C)C | |
| TCMBANKIN036913 | naringenin | (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; ZINC1785; Spectrum2_000325; 2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; (-)-Naringenin; SDCCGMLS-0066570.P001; (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one; MLS000574861; KBio2_000727; CHEBI:50201; HMS3468H18; ALBB-015405; NCGC00017346-01; BBL010488; AJ-08090; DivK1c_000118; BB 0261506; (S)-2,3-dihydo-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; CAS-480-41-1; KBio3_001454; SC-85987; 4H-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2R)-; AIDS-001417; NINDS_000118; SCHEMBL17166263; Spectrum3_000567; 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; (2R)-naringenin; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-chromanone; BSPBio_001954; BB_NC-1001; MCULE-5852778653; NCGC00163598-01; BG01564988; MFCD03265520; naringenin ; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; (2R)-5,7,4'-trihydroxyflavone; AKOS004119880; CHEBI:17846; ST24036200; AC1LDI7C; KBioGR_000508; ZINC00156701; Phytochemistry 8: 127 (1969); R6691; Asahina; 4',5, 7-Trihydroxyflavanone; N1370; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; C00509; 480-41-1; KBio2_003295; (2R)-4',5,7-trihydroxyflavanone; (+)-naringenin; Spectrum_000247; ZB000410; NAR; pelargidanon 1602; (R)-naringenin; IDI1_000118; STK801623; Spectrum5_001423; MolPort-002-507-277; Spectrum4_000124; 17654-19-2; KBio1_000118; KBioSS_000727; (+)-(2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2R)-4',5,7-trihydroxyflavan-4-one; NCGC00016457-01; STOCK1N-05989; KBio2_005863; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; AIDS001417; BG00617674; TNP00287; (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; SPECTRUM1500746; YSO1; SMR000156272; 4',5,7-triOH-Flavone; SPBio_000329 | C15H12O5 | 272.253 | c1(O[H])c([H])c([H])c([C@]2([H])Oc(c([H])c(O[H])c([H])c3O[H])c3C(=O)C2([H])[H])c([H])c1[H] |
| TCMBANKIN057911 | se | selenium | H2Se | 78.97 g/mol | [Se] |
| TCMBANKIN058178 | Daphnetol | 5-18-03-00211 (Beilstein Handbook Reference); AIDS-026334; HSCI1_000053; NSC 633563; EU-0000106; ZINC00057753; AIDS026334; 2H-1-Benzopyran-2-one, 7,8-dihydroxy- (9CI); KBio1_001904; 7,8-Dihydroxy-2H-1-benzopyran-2-one; KBioGR_001808; 7,8-Dihydroxycoumarin; 7,8-dihydroxy-coumarin; 7,8-dihydroxychromen-2-one; NCGC00015349-01; D5564_SIGMA; Daphnetin; CHEBI:17313; Oprea1_044324; 486-35-1; NSC633563; Spectrum3_000784; KBio3_001708; COUMARIN, 7,8-DIHYDROXY-; 7,8-dihydroxy-2H-chromen-2-one; Lopac0_000330; ST5308908; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-; Spectrum4_001254; BSPBio_002488; C03093; Lopac-D-5564; DivK1c_006960; EINECS 207-632-8; 630764_ALDRICH; BRN 0009372; EU-0100330; SpecPlus_000864; InChI=1/C9H6O4/c10-6-3-1-5-2-4-7(11)13-9(5)8(6)12/h1-4,10,12; 7,8-dihydroxy-2-chromenone; 4,8-Dihydroxycoumarin; AC-5538; ZINC21992842; 4,8-Dihydroxy-2H-chromen-2-one; BC216210; 7,8-dihydroxycoumarin; AKOS006290013; AK516453; daphnetin | C9H6O4 | 178.14 g/mol | C1=CC(=C(C2=C1C=CC(=O)O2)O)O |
| TCMBANKIN058519 | (-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; | KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate | C22H18O11 | 458.4g/mol | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O |
| TCMBANKIN059336 | tauroursodeoxycholic acid | tauroursodeoxycholicacid; ursodeoxycholicacid; ursodeoxycholic acid | C26H45NO6S | 499.7 g/mol | CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C |
| TCMBANKIN059579 | oridonin | C20H28O6 | 364.4 g/mol | CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C | |
| TCMBANKIN059932 | chrysophanol | C15H10O4 | 254.24 | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O | |
| TCMBANKIN060532 | corosolic acid | C30H48O4 | 472.7 g/mol | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1C)C)C(=O)O | |
| TCMBANKIN061570 | curcumin | (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin | IC21H20O6 | 368.4 g/mol | COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O |
| TCMBANKIN061952 | Crude fiber | SiO2 | O=[Si]=O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000002 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Sign or Symptom | phenotype | |
| TCMBANKDI000004 | Pathological Conditions, Signs and Symptoms | Constitutional symptom | Sign or Symptom | phenotype | |
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000011 | Pathological Conditions, Signs and Symptoms | Abnormality of the digestive system; Constitutional symptom | Sign or Symptom | phenotype | |
| TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI000035 | Digestive System Diseases; Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI000044 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000064 | Digestive System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI000074 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000092 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI000129 | Infections; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000439 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI000586 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI000771 | Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of the immune system | Sign or Symptom | phenotype | |
| TCMBANKDI000802 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument | Finding | phenotype | |
| TCMBANKDI001152 | Infections; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001279 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases | Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI001299 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI001526 | Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001701 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001706 | Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI001856 | Pathological Conditions, Signs and Symptoms; Digestive System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001965 | Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI002231 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI002297 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI002340 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI002512 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI002557 | Eye Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI002657 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI003037 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Sign or Symptom | phenotype | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003394 | Pathological Conditions, Signs and Symptoms | Abnormality of the nervous system | Sign or Symptom | phenotype | |
| TCMBANKDI003411 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI003501 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI003932 | Neoplasms; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI004134 | - | Abnormality of the respiratory system | Finding | phenotype | |
| TCMBANKDI005094 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Sign or Symptom | phenotype | |
| TCMBANKDI005098 | Infections; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005132 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005137 | Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | group | |
| TCMBANKDI005153 | Female Urogenital Diseases and Pregnancy Complications | - | Disease or Syndrome | disease | |
| TCMBANKDI005395 | Female Urogenital Diseases and Pregnancy Complications; Infections; Male Urogenital Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI005557 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005658 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI006055 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI006154 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI006156 | Digestive System Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI006259 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI006321 | Musculoskeletal Diseases | - | Acquired Abnormality | disease | |
| TCMBANKDI006328 | - | Abnormality of the genitourinary system | Disease or Syndrome | phenotype | |
| TCMBANKDI006612 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI007087 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI007111 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007123 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007295 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI007520 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI007651 | Pathological Conditions, Signs and Symptoms | - | Disease or Syndrome | disease | |
| TCMBANKDI007765 | Digestive System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007770 | Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases | Abnormality of the respiratory system | Sign or Symptom | phenotype | |
| TCMBANKDI008105 | Infections; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI008166 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI008314 | Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI008867 | Otorhinolaryngologic Diseases | Abnormality of the immune system; Abnormality of the ear | Disease or Syndrome | disease | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009278 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI009389 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI009702 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | phenotype | |
| TCMBANKDI009773 | Pathological Conditions, Signs and Symptoms; Immune System Diseases; Hemic and Lymphatic Diseases | Abnormality of the immune system; Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI009870 | - | Abnormality of the voice | Finding | disease | |
| TCMBANKDI009912 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Sign or Symptom | phenotype | |
| TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI009970 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI010048 | Infections; Respiratory Tract Diseases | Abnormality of the immune system; Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI010067 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI010160 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI010507 | - | - | Sign or Symptom | phenotype | |
| TCMBANKDI010589 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | Abnormality of the integument | Disease or Syndrome | disease | |
| TCMBANKDI010667 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011174 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI011557 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI011596 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011827 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI011845 | - | - | Laboratory Procedure | phenotype | |
| TCMBANKDI012157 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | group | |
| TCMBANKDI012234 | Female Urogenital Diseases and Pregnancy Complications; Infections; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI012325 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI012354 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI012932 | Infections; Immune System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI012979 | Immune System Diseases; Chemically-Induced Disorders | - | Pathologic Function | group | |
| TCMBANKDI013094 | Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI013278 | Infections; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI013347 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI013495 | Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI013541 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI014088 | Respiratory Tract Diseases; Cardiovascular Diseases | Abnormality of the respiratory system; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI014161 | Stomatognathic Diseases | Abnormality of the immune system; Abnormality of head or neck | Disease or Syndrome | group | |
| TCMBANKDI014272 | Nervous System Diseases | Abnormality of the nervous system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI014906 | Eye Diseases | Abnormality of the eye | Acquired Abnormality | disease | |
| TCMBANKDI015068 | Infections; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015212 | Infections; Respiratory Tract Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI015238 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015310 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015589 | Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015757 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI016263 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI016425 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Immune System Diseases | Abnormality of the genitourinary system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI016429 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI016612 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI016946 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI017008 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017181 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI017194 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI017267 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI017308 | Endocrine System Diseases | Abnormality of the endocrine system; Growth abnormality | Pathologic Function | phenotype | |
| TCMBANKDI017324 | Pathological Conditions, Signs and Symptoms | Abnormality of the digestive system; Abnormality of connective tissue | Disease or Syndrome | disease | |
| TCMBANKDI017387 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI017950 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI018129 | Immune System Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018151 | Digestive System Diseases; Nutritional and Metabolic Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI018635 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI018731 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | disease | |
| TCMBANKDI018992 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI019307 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020257 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020284 | Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020782 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI020794 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI020911 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI021151 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI021181 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI021339 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | group | |
| TCMBANKDI021442 | Infections; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI021784 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Cell or Molecular Dysfunction | phenotype | |
| TCMBANKDI022161 | Eye Diseases | Abnormality of the immune system; Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI022322 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI022361 | Pathological Conditions, Signs and Symptoms; Eye Diseases | - | Sign or Symptom | phenotype | |
| TCMBANKDI022473 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI022571 | Infections; Animal Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI022727 | Infections; Respiratory Tract Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI022910 | Female Urogenital Diseases and Pregnancy Complications; Infections; Male Urogenital Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI022943 | Respiratory Tract Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023253 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI023331 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI023498 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023834 | Nervous System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI023906 | Eye Diseases | Abnormality of the eye | Finding | phenotype | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024472 | Digestive System Diseases; Chemically-Induced Disorders; Mental Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI024520 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immune System Diseases; Hemic and Lymphatic Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024877 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI025194 | - | - | Finding | disease | |
| TCMBANKDI025414 | Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI025770 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI026360 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI026874 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI026963 | Pathological Conditions, Signs and Symptoms | - | Acquired Abnormality | disease | |
| TCMBANKDI027014 | Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI027040 | Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027628 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI028064 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI028305 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI028664 | - | - | Finding | phenotype | |
| TCMBANKDI028799 | Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI028880 | Infections; Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI028908 | Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases | Abnormality of the eye | Disease or Syndrome | phenotype | |
| TCMBANKDI028918 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Finding | phenotype | |
| TCMBANKDI028997 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI029152 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI029220 | Nutritional and Metabolic Diseases; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI029321 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI029456 | Eye Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI029791 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI029899 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI030268 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI030664 | Respiratory Tract Diseases | Abnormality of metabolism/homeostasis; Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI032257 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI032474 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI032496 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI032498 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab